Status:
COMPLETED
Rosiglitazone Effect on Mitochondria and Lipoatrophy
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the effect of rosiglitazone on limb fat and mitochondrial indices in HIV-1-infected subjects receiving stable antiretroviral therapy that does not contain stavu...
Detailed Description
This is a phase II, randomized, double-blind, placebo-controlled study of rosiglitazone for the treatment of HIV-associated lipoatrophy. Subjects will receive blinded study treatment for 48 weeks. Thi...
Eligibility Criteria
Inclusion
- Lipoatrophy
- Thymidine sparing ARV for at least 24 weeks
- Prior thymidine NRTIs for at least 12 months
Exclusion
- Diabetes
- Heart failure
- Liver disease
- Hormonal therapies
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00367744
Start Date
July 1 2006
End Date
December 1 2008
Last Update
February 6 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinc Foundation
Cleveland, Ohio, United States, 44106
2
University Hospitals of Cleveland/Case Western Reserve University
Cleveland, Ohio, United States, 44141